Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy

• Published in: Journal of oncology pharmacy practice 2020-04, Vol.26 (3), p.564-571
• Main Authors: Weis, Taylor M, Hough, Shannon, Reddy, Haritha G, Daignault-Newton, Stephanie, Kalemkerian, Gregory P
• Format: Article
• Language: English
• Subjects: Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Carcinoma, Non-Small-Cell Lung - drug therapy; Chemotherapy; Clinical trials; Female; Humans; Immune checkpoint; Immunotherapy; Immunotherapy - methods; Lung cancer; Lung Neoplasms - drug therapy; Male; Middle Aged; Monoclonal antibodies; Neoplasm Recurrence, Local; Nivolumab - administration & dosage; Non-small cell lung carcinoma; Pembrolizumab; Platinum; Platinum - administration & dosage; Response rates; Retrospective Studies; Small cell lung carcinoma; Statistical analysis; Targeted cancer therapy; Toxicity
• ISSN: 1078-1552; 1477-092X
• DOI: 10.1177/1078155219855127

Purpose Immunotherapy is a relatively new treatment modality for advanced non-small cell lung cancer following platinum-based chemotherapy. Nivolumab, pembrolizumab, and atezolizumab demonstrated superior outcomes and improved tolerability compared to standard treatment in randomized controlled trials; however, these studies vary significantly in inclusion criteria and study design. To our knowledge, the efficacy and safety of nivolumab and atezolizumab following platinum-based chemotherapy have not been directly compared to one another in a real-world clinic setting. Methods We retrospectively compared immunotherapy response rates and toxicity in patients with stage IV or recurrent non-small cell lung cancer following progression during or after platinum-based chemotherapy. Results Among 124 eligible patients, the objective response rate was 14.8% in the nivolumab group (n = 81) vs. 13.9% in the atezolizumab group (n = 43) (p = 0.897). Median overall survival was 8.4 months with nivolumab (95% confidence interval (CI), 6.3 to 11.2) vs. 6.5 months with atezolizumab (95% CI, 4.7 to not reached). Median progression free survival was 2.2 months (95% CI, 1.7 to 2.8) and 2.0 months (95% CI, 1.8 to 2.7) in the nivolumab and atezolizumab groups, respectively. Treatment-related adverse events occurred in 70.4% of patients in the nivolumab group and 65.1% in the atezolizumab group. Conclusions There was no statistically significant difference in efficacy outcomes in patients with non-small cell lung cancer who received atezolizumab or nivolumab after progression during or after platinum-based chemotherapy. Response rates in this study were numerically lower than response rates observed in the landmark randomized controlled trials leading to approval of immunotherapy in this setting. Rates of treatment-related adverse events were similar between groups.